| Name | Title | Contact Details |
|---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
We are a medical group of physicians and health professionals that specialize in gastrointestinal disorders, nutrition and digestive health. Our offices are conveniently located throughout South Florida, Orlando and Fort Myers.
Dracen is a privately funded biotech company developing drugs in the area in of immuno metabolism.
Meda is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Basic Research, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.